Cornerstone, MedImmune dissolve development pact; Corey Goodman backs PhyloTech; Viroxis waiting on new funding;

@FierceBiotech: Only the biggest developers can play the biosimilar game. Article | Follow @FierceBiotech

@JohnCFierce: If I was master of the universe, I'd have Pfizer buy Genzyme, Sanofi buy Biogen and Merck buy Allergan. All announced on the same day. | Follow @JohnCFierce

> Cornerstone Therapeutics and MedImmune are ending their collaboration on new drugs for chronic inflammation. Cornerstone says it is looking for a new partner to replace MedImmune. Story

> The high-profile biotech entrepreneur Corey Goodman is one of the angel investors backing PhyloTech, which is developing new technology to swiftly identify bacteria in food and water. Report

> San Antonio-based start-up Viroxis is waiting on a $2.5 million in funding from the Texas Emerging Technology Fund to finance the late-stage study of a new botanical therapy. Story

> The FDA has approved Kamada's Glassia (Alpha 1 Proteinase inhibitor, also known as Alpha-1-Antitrypsin) for the treatment of Alpha 1 deficiency. Kamada release

And Finally... Men who rely on ED drugs are twice as likely unmedicated men to contract a sexually transmitted disease. Story

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."